Linaclotide: a new option for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation in adults.
Chronic idiopathic constipation (CC) and irritable bowel syndrome with predominant constipation (IBS-C) are the 2 most common conditions among functional gastrointestinal disorders. Despite current multiple therapeutic options, treatment remains challenging and dissatisfactory to many patients. Linaclotide is a novel therapeutic agent, which is a guanylate cyclase receptor agonist that stimulates water secretion from the intestinal epithelium by promoting chloride and bicarbonate efflux into the lumen through activation of the cystic fibrosis transmembrane conductance regulator. Clinical trials have demonstrated that linaclotide is effective, safe and well tolerated in patients with CC and IBS-C. This review article highlights the mechanism of action of linaclotide, reviews published literature based on a search of databases, including MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL), up to February 2013, and compares its utility with other currently available agents.
Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Colleen H
CH
Parker
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Yuhong
Y
Yuan
Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Louis Wing Cheong
LW
Liu
clinical trial; constipation; irritable bowel syndrome; linaclotide; mechanism of action